The Therapeutic Goods Administration has broadened the range of clinicians eligible to participate in psychedelic-assisted psychotherapy, a move set to speed up recruitment and improve patient access across Emyria’s national Empax network.
- TGA widens eligible therapist disciplines under Authorised Prescriber scheme
- Includes nursing, occupational therapy, and Aboriginal health workers
- Benefits expected in second half of 2026 after final approvals
- Emyria anticipates improved clinic utilisation and workforce diversity
- Regulatory change supports culturally safe care and patient access
TGA Broadens Clinical Workforce for Psychedelic Therapy
Emyria Limited (ASX:EMD) has welcomed a significant regulatory update from the Therapeutic Goods Administration (TGA) that expands the pool of clinicians eligible to participate in psychedelic-assisted psychotherapy under the Authorised Prescriber (AP) scheme. Previously, the psychedelic-assisted psychotherapy "dyad" required a clinical psychologist or medical practitioner during dosing sessions. The TGA’s revised recommendations now allow a broader range of registered therapists, including those in nursing, occupational therapy, and Aboriginal and Torres Strait Islander health workers, to fulfill this role, subject to professional discretion.
Implications for Empax Clinic Network Recruitment
This regulatory shift is poised to accelerate recruitment across Emyria’s Empax clinic network, which spans over 100 clinicians nationwide. By reducing reliance on clinical psychologists and enabling more flexible dyad configurations, Emyria expects to improve clinic utilisation and expand patient access to psychedelic-assisted mental health treatments. The inclusion of Aboriginal and Torres Strait Islander health workers also signals a push towards culturally safe care, aligning with broader healthcare equity goals.
Emyria has already begun revising workforce planning in anticipation of the changes, which will require final TGA endorsement and ethics committee review before implementation. The company projects the benefits to materialise in the second half of calendar year 2026, aligning with its ongoing national rollout of Empax clinics.
Regulatory Engagement Reflects Growing Clinical Confidence
Executive Chair Greg Hutchinson described the update as a "welcome and pragmatic step" that demonstrates the TGA’s responsiveness to emerging real-world evidence and operational experience in psychedelic-assisted psychotherapy. The company anticipates further adjustments to the regulatory framework as clinical data and treatment experience mature.
Emyria’s recent expansion efforts, including the activation of its first Victorian Empax clinic with over 30 trained therapists, provide a foundation to capitalise on this regulatory change. The company’s ongoing clinic launches in New South Wales and Victoria, alongside a global partnership program targeting international drug sponsors, underscore a strategic push to scale its mental health treatment platform nationally and internationally Victorian Empax clinic operational and Emyria Advances National Clinic Network.
Navigating Implementation and Future Opportunities
While the final TGA endorsement is pending, Emyria’s experience with regulatory processes positions it well to adapt care models and training programs swiftly. The expanded therapist eligibility not only promises to ease recruitment bottlenecks but also enhances the diversity and cultural competence of the clinical workforce, an increasingly important factor in mental health service delivery.
As psychedelic-assisted psychotherapy continues to gain traction, regulatory flexibility will be critical to scaling treatment access. Emyria’s proactive approach to integrating these changes could provide a competitive edge in a nascent but rapidly evolving sector.
Bottom Line?
Emyria’s ability to swiftly implement the TGA’s expanded therapist criteria will be key to unlocking greater clinic utilisation and patient reach in the second half of 2026.
Questions in the middle?
- How quickly will final TGA endorsement and ethics approvals be secured?
- What impact will workforce diversification have on patient outcomes and clinic efficiency?
- Could further regulatory changes expand the scope or scale of psychedelic-assisted psychotherapy?